Ken Mariash, CEO of Sinaptica Therapeutics, talks with EisnerAmper's TechTalk host Janina Teoxon about the novel approach his startup is taking to develop a non-drug therapy to treat Alzheimer's. In this episode, Ken acknowledges the repeated failures the industry has faced on its quest to find a cure for the disease and explains why his personalized and connectome-targeted neuromodulation approach has gained the FDA breakthrough designation. Learn how Ken and his team are overcoming investor skepticism as their promising treatment emerges.